Natixis Kodiak Sciences Inc. Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.04 - $9.48 $215,097 - $404,587	-42,678 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.09 - $89.45 $261,833 - $3.3 Million	36,930 Added 642.48%	42,678 $329,000
Q4 2021 Feb 14, 2022	SELL	$80.85 - $128.49 $447,504 - $711,192	-5,535 Reduced 49.06%	5,748 $487,000
Q3 2021 Nov 12, 2021	BUY	$81.97 - $106.94 $924,867 - $1.21 Million	11,283 New	11,283 $1.08 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $276M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.